Cargando...

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review

INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the search for therapies that not only effectively...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: McGill, Janet B.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2014
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4065283/
https://ncbi.nlm.nih.gov/pubmed/24729157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0063-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!